The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 28 | — | 20.1x | Below average | |
Growth | 86 | 107.7% | 5.6% | Above average | |
Quality | 43 | -32.4% | 7.6% | Near average | |
Safety | 62 | -5.8x | 0.4x | Near average | |
Capital Return | 54 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
AnaptysBio, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy AnaptysBio, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
AnaptysBio stock shows complete stability in the average price target at $83.14 over the past thirty days, with no recent revisions from the three analysts covering the stock. This stability reflects a state of anticipation awaiting new clinical or financial catalysts, especially since the current price ($59.71) is trading at a significant discount to the average target, indicating a valuation gap that has yet to be closed.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.